Corporate | 7 October 2004 14:33
STRATEC with new DNA/RNA stabilisation technology
Corporate-news announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
STRATEC with new DNA/RNA stabilisation technology
Birkenfeld, Oct. 7th, 2004
STRATEC Biomedical Systems AG, has concluded a licence agreement with Cyclops
Genome Sciences Limited to obtain worldwide exclusive rights to a technology
for the stabilisation and purification of RNA and DNA from pathogens and
certain other applications.
As the infectiousness of samples represents a significant hazard, one of the
crucial advantages of this unique technology is that it is expected to
transform the infectious RNA viruses, e.g. in whole blood, blood plasma or
tissue, into non-infectious material instantaneously at the moment of
stabilisation of the RNA.
The patented technology, known as “MRT” (Modified RNA Technology), was
developed by Cyclops Genome Sciences.
Having secured these exclusive rights to MRT, STRATEC is able to provide its
customers with a genuine competitive edge by supplementing existing
technologies.
About STRATEC Biomedical Systems AG
STRATEC Biomedical Systems AG(http://www.stratec-biomedical.de) designs and
manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems
together with their own reagents to laboratories and research institutes
around the world. The company develops its products on the basis of its own
patented technologies. Shares in the company
(WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment
of the Frankfurt Stock Exchange, in the trading segment Gate-M of the
Stuttgart Stock Exchange and on other exchanges.
Further information can be obtained from:
STRATEC Biomedical Systems AG
Investor Relations
André Loy
Gewerbestraße 37
D-75217 Birkenfeld
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
eMail: ir@stratec-biomedical.de
end of message, (c)DGAP 07.10.2004
——————————————————————————–
WKN: 728900; ISIN: DE0007289001; Index:
Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart;
Freiverkehr in Berlin-Bremen, Düsseldorf und München
071433 Okt 04